GLOW

GHK-Cu + BPC-157 + TB-500 blend

GLOW (GHK-Cu + BPC-157 + TB-500 blend) is a blends & other research compound. Recovery/skin stack — GHK-Cu for collagen/remodeling, BPC-157 and TB-500 for systemic repair and angiogenesis.

How GLOW works

Recovery/skin stack — GHK-Cu for collagen/remodeling, BPC-157 and TB-500 for systemic repair and angiogenesis.

Proposed benefits

A combination formula — proposed benefits reflect the sum of its individual components.

Where to get GLOW

GLOW is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.

The evidence for GLOW

Graded by what exists behind each claim.

✅ Clinically validated

• No trial of the blend, and there could not be one — GLOW is a compounded combination of GHK-Cu, BPC-157 and TB-500 sold as a single vial. Read each component's clinical tier; the blend inherits their evidence and adds none of its own.

📊 Correlative data

• One of the most popular blends in the research space, used for skin, hair and connective tissue. The reported experience is a broader effect than any single component, which is what you would expect from three compounds and not evidence of synergy.
• The practical trade-off is dosing control: a fixed ratio means you cannot titrate one component without moving the others.

🧪 Theoretical / extrapolated

• Three distinct mechanisms in one vial — GHK-Cu delivers copper and shifts repair-associated gene expression, BPC-157 is angiogenic, TB-500 is pro-migratory. The mechanistic case for combining them is that they act at different stages of the same repair sequence rather than competing.
• The same three mechanisms carry the same unresolved proliferation question each carries alone, and combining them does not make it smaller.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What GLOW actually does

Start with what is actually in the vial, because this site carries the numbers and no page uses them. The blend record for GLOW is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in one vial, reconstituted with 200 units of bacteriostatic water, dosed at 10 units. Ten units is one twentieth of the vial, so a single injection delivers 2.5 mg of GHK-Cu, 500 mcg of BPC-157 and 500 mcg of TB-500. Those are the real per-dose amounts and everything below follows from them.

Now the calculation nobody does: this is a copper injection. GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine carrying a bound Cu²⁺ ion. GHK itself weighs about 340 Da; the copper complex weighs about 402 Da, so copper is roughly 16% of the mass. At 2.5 mg of GHK-Cu per injection, that is approximately 400 micrograms of elemental copper delivered subcutaneously per dose.

Put that number in context, because it is the most important thing on this page. The adult reference intake for copper is roughly 900 mcg per day by mouth, of which intestinal absorption captures something like a third to a half — call it 300 to 450 mcg actually entering the body. A daily GLOW injection therefore delivers approximately one full day’s worth of absorbed copper, by a route that bypasses the intestine entirely.

The route is the point. Copper uptake at the gut is regulated — the transporter is downregulated when stores are adequate, excess is bound by metallothionein in the enterocyte and shed, and the main excretory route is biliary. A subcutaneous injection skips every one of those control points. Nobody selling this blend mentions copper at all, and copper is 16% of its largest component by weight.

What GHK-Cu does once it is there. The peptide is credited with stimulating blood vessel and nerve outgrowth, increasing collagen, elastin and glycosaminoglycan synthesis, supporting dermal fibroblast function, improving tissue repair in skin, lung, bone, liver and stomach lining, suppressing NF-κB, repairing DNA and activating proteasomal cell cleansing Pickart 2018. That is an extraordinarily long list and it is worth saying where it comes from: the review is authored by the researcher who discovered the peptide, and it is a review of accumulated cell and animal work rather than a trial. Take it as a map of what has been observed, not as a claim about what an injection does to a person.

The mechanistic result that is specific and measured runs against the marketing. GHK-Cu stimulates matrix metalloproteinase-2 expression in fibroblast cultures Simeon 2000. MMP-2 is a gelatinase; it degrades matrix. So this molecule does not simply build collagen — it drives remodeling, which means synthesis and breakdown together. That is the correct mechanism for scar revision and for reorganizing disorganized matrix, and it is a genuinely different claim from ‘more collagen’.

A warning about the hair-growth citation, because vendors get this wrong constantly. The frequently cited study showing stimulation of human hair follicle elongation and dermal papilla cell proliferation used AHK-Cu — alanyl-histidyl-lysine copper — not GHK-Cu Pyo 2007. Different first residue, different molecule. It is a real and interesting result — follicle elongation and reduced dermal papilla apoptosis with a raised Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP — but it is not evidence about the peptide in this vial.

And note the concentration in that study, because it changes how you read the dose. AHK-Cu worked at 10⁻¹² to 10⁻⁹ M Pyo 2007 — 1 picomolar to 1 nanomolar. A 2.5 mg dose of a 402 Da peptide is 6.2 micromoles; distributed through roughly 42 liters of body water that is about 150 nanomolar, and through plasma alone it is nearer 2 micromolar. That is 150 to 2,000 times above the concentration range in which the related copper-peptide worked on follicles. For molecules with bell-shaped dose-response curves — and copper peptides are repeatedly described that way — more is not obviously better, and this is the first page anywhere to put the two numbers side by side.

The other two components, briefly, because each has its own page. TB-500 is the synthetic actin-binding domain of thymosin β4, not thymosin β4 itself; the parent protein and that fragment both promoted dermal wound repair in db/db diabetic and aged mice Philp 2003. BPC-157 is a 15-residue sequence from gastric juice with a substantial preclinical literature across striated, smooth and cardiac muscle Staresinic 2022 and no human trial.

Cell, rodent, human — and where it stops

Step zero, and it decides the whole page: there is no GLOW study. No trial of this blend has been run, and none could be registered in a form that would mean anything — a fixed-ratio three-drug combination in which no component has an approved indication has nothing to be tested against. Everything below is the evidence for the parts.

GHK-Cu, in cells. Stimulation of MMP-2 expression in fibroblast cultures Simeon 2000; the wider body of collagen, elastin, glycosaminoglycan, angiogenesis, anti-inflammatory and gene-expression work summarized by the peptide’s discoverer Pickart 2018. In human tissue: the follicle work is AHK-Cu, a different tripeptide Pyo 2007. In humans given GHK-Cu by injection: nothing published. The human use of GHK-Cu with any published support is topical and cosmetic.

TB-500 and thymosin β4, in animals. Thymosin β4 and a synthetic peptide containing its actin-binding domain both promoted dermal wound repair in db/db diabetic mice and in aged mice Philp 2003. That is a genuine, mechanistically coherent animal result and it is the strongest evidence any component of this blend has for a skin claim.

TB-500 in humans, and here is a finding that should change how this compound is discussed. The paper everyone cites as ‘the European randomized trial of thymosin β4 in venous ulcers’ is a study description, not a result. It sets out the design — three sequential dose groups, 24 patients each randomized 3:1 against placebo, 10 sites in Italy and Poland, topical dosing, 72 patients treated for 84 days — and then reports, verbatim: ‘The study is ongoing and a total of 21 patients have been enrolled so far in the first treatment group at the lower dose’ Guarnera 2007. No healing rate. No efficacy outcome. No result of that trial appears in the indexed literature to this day.

The one real human pharmacology study, and it is not this molecule or this route. A first-in-human phase 1 of recombinant human thymosin β4: 54 healthy subjects given single intravenous doses from 0.05 to 25 mcg/kg, plus 30 subjects at 0.5, 2.0 or 5.0 mcg/kg once daily for 10 days. Adverse events were mild to moderate, there were no dose-limiting toxicities or serious adverse events, Cmax and AUC rose with dose, and there was no obvious accumulation after repeated dosing Wang 2021. Two differences from what is in this vial: that study used the full-length 43-residue protein, not the 7-residue actin-binding fragment sold as TB-500, and it used the intravenous route. Its top single dose, 25 mcg/kg, is about 2.25 mg in a 90 kg person — the same order of magnitude as the 500 mcg of TB-500 in a GLOW dose, which is the one useful calibration available.

BPC-157 in humans: nothing. An extensive preclinical literature across muscle types Staresinic 2022 and no published randomized human trial.

The obstacles, named one at a time. (1) A blend inherits the weakest tier, not the average. One component has decades of cell biology and no injectable human data Pickart 2018; one has an animal wound result and a famous trial that never reported Philp 2003 Guarnera 2007; one has no human trial at all Staresinic 2022. (2) The fixed ratio removes the only control you have. At 5:1:1 you cannot raise GHK-Cu for a skin effect without raising the other two, and you cannot lower the copper load without lowering everything. (3) Synergy is asserted and has never been tested — not in a dish, not in an animal, not in a person. Three mechanisms in one syringe is an argument, not a result. (4) The copper is unaccounted for: none of the component literature addresses repeated parenteral copper delivery, because none of it studied a daily injection. (5) The site’s own dose string is internally inconsistent — it reads ‘1-3mg GHK-Cu & 200-600mcg BPC,TB,KPV’, naming KPV, which is not one of the three components in the blend definition. The computed per-dose amounts (2.5 mg / 500 mcg / 500 mcg) fall inside those ranges, but a fourth peptide appears in the dosing line and nowhere in the formula.

GLOW pharmacokinetics — how much of it actually gets in

The catalog says ‘Varies by component’. That is correct and it understates the problem: this vial contains two clocks that differ by roughly four orders of magnitude, and only one of them is a peptide.

Clock one: the peptides, and they are fast. GHK-Cu is a 402 Da tripeptide with a free N-terminus. Aminopeptidases on vascular endothelium remove residues from that end, and serum endopeptidases cut internally; there is no D-amino acid, no acetyl cap, no amide and no ring anywhere in it to slow that down. A tripeptide of this kind is a minutes-scale molecule in plasma. TB-500 is a 7-residue acetylated fragment, also small and also linear. BPC-157 is 15 residues and is described as unusually stable in gastric juice, which is a statement about acid and pepsin rather than about plasma peptidases. No published plasma half-life exists for any of the three in humans — the only human pharmacokinetics in the entire component literature is for full-length recombinant thymosin β4 given intravenously, where exposure was dose-proportional with no accumulation over 10 daily doses Wang 2021.

Clock two: the copper, and it is slow. When the tripeptide is hydrolyzed the copper does not leave. It is handed to albumin and transcuprein, taken up by the liver, incorporated into ceruloplasmin and returned to plasma, and excreted mainly in bile. That is a body pool with a turnover measured in weeks, not minutes. So the peptide half of GHK-Cu is gone before the injection site stops stinging, and the metal half is still being handled a month later. Every discussion of this compound treats it as a peptide with a peptide’s kinetics; half its mechanism has the kinetics of a mineral.

The accumulation arithmetic. At roughly 400 mcg of elemental copper per injection, a daily protocol delivers about 2.8 mg per week and, over a 12-week cycle, roughly 34 mg of copper — parenterally, bypassing intestinal regulation. Total body copper in an adult is on the order of 50 to 120 mg. A single long cycle of this blend is therefore in the same order of magnitude as the entire body copper content, delivered past the mechanism that exists to prevent exactly that. Biliary excretion can rise to compensate and probably does; the point is that nobody has measured whether it fully does, in anybody, on this protocol.

The oral barrier. Absolute for GHK-Cu and TB-500 — gastric acid, pancreatic proteases, brush-border peptidases and hepatic first-pass extraction behind them, with no transporter for either. BPC-157 is the exception the literature actually argues for, on the basis of stability in gastric juice, and that argument does not extend to the other two components of this vial.

The injectable comparator, which is the route in use. Subcutaneous injection, 29–31 gauge, once daily. Subcutaneous dosing removes the gut and the first-pass liver; it does not slow plasma peptidases, and for the copper it removes the only regulated step in the entire system. The single human dose-ranging study in the component literature used the intravenous route at 0.05 to 25 mcg/kg Wang 2021, so even the route people use has no direct human precedent here.

What would have to be true, and how you would know it was not

Four predictions, and the first two are blood tests that nobody running this compound has ever been told to order. They are cheap, they are on standard panels, and they are the only objective read-out this blend has.

1. Serum copper and ceruloplasmin should rise, and if they do not, the vial is not what it says. Roughly 400 mcg of elemental copper per dose, injected daily, past the regulated intestinal step. Draw copper and ceruloplasmin at baseline and again at 6 to 8 weeks on a daily protocol. This is the single most informative measurement available for GLOW and no published or anecdotal record of it exists. Two outcomes and both are worth having: a rise confirms the copper is arriving and quantifies how much the body is failing to clear; a completely flat result at 8 weeks of daily dosing means either that biliary excretion is fully compensating — genuinely reassuring, and currently unknown — or that the vial does not contain the copper complex it claims, which is a purity finding.

2. Zinc should be watched alongside it, because copper and zinc antagonize each other. Sustained copper loading is the classic route to a functional zinc deficit, and the symptoms — poor wound healing, hair shedding, taste change — are precisely the things somebody taking a ‘skin and repair’ blend would misread as the compound not working. Draw zinc with the copper at both time points. The prediction that argues against the product is that a long daily cycle moves the copper-to-zinc ratio in the wrong direction, and it has never been checked.

3. hs-CRP should not rise, and if it does the ceruloplasmin result is uninterpretable. Ceruloplasmin is an acute-phase reactant: it climbs with inflammation, with estrogen and in pregnancy, entirely independently of copper status. Draw hs-CRP at the same two time points. A ceruloplasmin rise with a flat hs-CRP is a copper signal; a ceruloplasmin rise alongside a CRP rise tells you nothing about copper at all. That confound is the reason a ceruloplasmin drawn alone would be a wasted test, and it is exactly the sort of thing left out of every protocol.

4. The visible effect should appear in the order the components predict, and the order is testable. The dermal wound-repair evidence for the thymosin fragment is animal and topical Philp 2003; the GHK-Cu evidence is remodeling — MMP-2 up, matrix reorganized Simeon 2000 — which is a months-scale process. So the prediction is that anything noticed in the first two weeks is not collagen and not remodeling: it is hydration, injection-site inflammation or expectation. Photograph one fixed area monthly under identical light and judge at 12 weeks, not at two.

What nobody has tested yet

Four experiments. The first one costs about the same as a month of the blend and would be the first objective data this product has ever generated.

1. Nobody has ever measured copper status on a copper-peptide protocol. Not serum copper, not ceruloplasmin, not erythrocyte copper, not urinary copper, not the copper-to-zinc ratio. The blend delivers about 400 mcg of elemental copper per injection by a route that bypasses intestinal regulation, and in the entire published and anecdotal record there is not one before-and-after copper panel. Twenty people posting paired draws would produce more information about the safety of injected copper peptides than currently exists anywhere.

2. Nobody has ever run a dose-response for injected GHK-Cu. The closest copper-peptide follicle data works at 1 picomolar to 1 nanomolar Pyo 2007 while a GLOW dose produces something like 150 nanomolar to 2 micromolar in the body. Nobody has tested whether a tenth of this dose, or a hundredth, does the same thing or more — and for a molecule class repeatedly described as having bell-shaped dose-response curves, that is not an academic question. It is entirely possible that the standard dose is on the wrong side of the curve, and nobody has looked.

3. Nobody has reported the result of the one randomized trial the component literature actually started. The venous ulcer study planned 72 patients across 10 European sites over 84 days with digital-planimetry wound areas and plasma thymosin β4 levels; the only published account reports 21 patients enrolled and no outcome Guarnera 2007. Somebody has that dataset. Publishing it, positive or negative, would settle the single most-cited claim made for TB-500.

4. Nobody has tested the blend against its own components. The entire commercial argument is that three mechanisms acting at different stages of one repair sequence are better together. The experiment is four arms — blend, GHK-Cu alone, BPC-157 plus TB-500, vehicle — in a rodent wound model, which is a design the component literature already uses Philp 2003. It has never been run, so synergy remains the one claim about GLOW that is specific to GLOW and the one claim with no evidence of any kind behind it.

GLOW — its own safety story, not its class's

The shared block on this page is the generic repair-peptide profile: angiogenesis, proliferation, the tumor question. Those apply and they are covered on each component’s own page. Three risks belong specifically to the blend, and the first one is not mentioned anywhere in this market.

1. Copper load, delivered past the body’s only regulator. About 400 mcg of elemental copper per injection, roughly 2.8 mg a week and 34 mg over a 12-week cycle, against a total body copper content on the order of 50 to 120 mg. Intestinal absorption — the step that normally prevents copper accumulation — is bypassed completely by a subcutaneous injection. Copper excess in its established forms causes hepatic injury and neurological effects, and the organ that carries the burden is the liver, because biliary excretion is the only real exit. A CMP with liver enzymes belongs on the same draw as the copper panel, and nobody orders either.

2. The fixed ratio makes every dose decision a compromise. At 50:10:10 there is no way to reduce the copper without reducing the two peptides, and no way to increase the peptides without increasing the copper. Anybody who wants more of the thymosin fragment for a tendon has to take five times as much GHK-Cu to get it. That is a structural safety property of a blend, not a dosing preference, and it is the strongest practical argument for buying the three components separately.

3. Daily subcutaneous injection is its own risk, independent of what is in the syringe. The usage pattern here is daily or five-days-on for 4 to 12 weeks, which is 20 to 60 injections per cycle. Repeated subcutaneous dosing into a small number of sites carries infection, sterile abscess, lipoatrophy and local fibrosis risk regardless of the contents, and GHK-Cu solutions are notably stinging on injection.

4. What the component safety record actually supports. The only controlled human safety data in the whole component literature is a phase 1 of full-length recombinant thymosin β4 given intravenously: 84 subjects, mild-to-moderate adverse events, no dose-limiting toxicities, no serious adverse events, no accumulation over 10 days Wang 2021. That is genuine reassurance about a different molecule by a different route for ten days. There is no human safety trial of GHK-Cu by injection, none of BPC-157 by any route Staresinic 2022, and none of this blend.

What zero means. There are 0 published adverse events for GLOW, because there has never been a study in which one could have been recorded. On a product delivering a metal by a route that bypasses the body’s regulation of that metal, an empty record is not a clean one.

Sources read for this page

• Pickart L, et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences 2018 · PMID 29986520
• Simeon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences 2000 · PMID 11045606
• Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research 2007 · PMID 17703734
• Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 2003 · PMID 12581423
• Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences 2007 · PMID 17495250
• Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine 2021 · PMID 34346165
• Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines 2022 · PMID 36551977

GLOW — safety, predicted from mechanism

GLOW — interference & stacking

Bloodwork to run alongside GLOW

Baseline first, then again at 8–12 weeks.

The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.

Check results you already have → · All 103 markers A–Z

GLOW — frequently asked questions

What GLOW is used for

GLOW appears under 1 goal in the goal router.

Related Blends & Other compounds

← Explore the full Protocol Vault

↑ Back to on this page